Details for Patent: 12,377,133
✉ Email this page to a colleague
Which drugs does patent 12,377,133 protect, and when does it expire?
Patent 12,377,133 protects YUVIWEL and is included in one NDA.
This patent has twenty patent family members in twelve countries.
Summary for Patent: 12,377,133
| Title: | Dry pharmaceutical formulations of CNP conjugates |
| Abstract: | A dry pharmaceutical formulation, wherein the pharmaceutical formulation comprises a CNP conjugate, a buffering agent and a bulking agent and wherein the CNP conjugate comprises a CNP moiety that is covalently and reversibly conjugated to a polymeric moiety. |
| Inventor(s): | Anja R. H. Skands, Ulrich Hersel, Charlotte PINHOLT, Stefan HEINIG |
| Assignee: | Ascendis Pharma Endocrinology Division AS |
| Application Number: | US17/428,604 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; |
Drugs Protected by US Patent 12,377,133
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ascendis | YUVIWEL | navepegritide | POWDER;SUBCUTANEOUS | 219164-001 | Feb 27, 2026 | RX | Yes | Yes | 12,377,133 | ⤷ Start Trial | Y | INCREASE OF LINEAR GROWTH IN PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | |||
| Ascendis | YUVIWEL | navepegritide | POWDER;SUBCUTANEOUS | 219164-002 | Feb 27, 2026 | RX | Yes | Yes | 12,377,133 | ⤷ Start Trial | Y | INCREASE OF LINEAR GROWTH IN PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | |||
| Ascendis | YUVIWEL | navepegritide | POWDER;SUBCUTANEOUS | 219164-003 | Feb 27, 2026 | RX | Yes | Yes | 12,377,133 | ⤷ Start Trial | Y | INCREASE OF LINEAR GROWTH IN PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,377,133
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020223441 | ⤷ Start Trial | |||
| Australia | 2025210778 | ⤷ Start Trial | |||
| Brazil | 112021014495 | ⤷ Start Trial | |||
| Canada | 3129352 | ⤷ Start Trial | |||
| China | 113423384 | ⤷ Start Trial | |||
| China | 117281783 | ⤷ Start Trial | |||
| European Patent Office | 3923906 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
